{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:16:39Z","timestamp":1790486199742,"version":"4.1.0"},"reference-count":40,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2019.10043","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T12:38:04Z","timestamp":1550147884000},"source":"Crossref","is-referenced-by-count":8,"title":["Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer"],"prefix":"10.3892","author":[{"given":"Emanuel","family":"Buck","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, University Hospital Heidelberg, D\u201169120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sprick","sequence":"additional","affiliation":[{"name":"HI\u2011STEM gGmbH\/German Cancer Research Center Heidelberg (MRS), D\u201169120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Gaida","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Center for Tumor Diseases, University Hospital Heidelberg, D\u201169120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Gr\ufffdllich","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, D\u201169120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, D\u201169120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Herpel","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Center for Tumor Diseases, University Hospital Heidelberg, D\u201169120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bruckner","sequence":"additional","affiliation":[{"name":"Institute for Medical Biometry and Informatics, University of Heidelberg, D\u201169120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Koschny","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Heidelberg, D\u201169120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2019,2,14]]},"reference":[{"key":"key20200714085855_b1-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1515\/CCLM.2000.128","article-title":"Cancer therapy and polymorphisms of cytochromes P450","volume":"38","author":"MacLeod","year":"2000","journal-title":"Clin Chem Lab Med"},{"key":"key20200714085855_b2-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2174\/138920008783571774","article-title":"Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues","volume":"9","author":"Pavek","year":"2008","journal-title":"Curr Drug Metab"},{"key":"key20200714085855_b3-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev.pharmtox.43.100901.140251","article-title":"Human extrahepatic cytochromes P450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts","volume":"43","author":"Ding","year":"2003","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"key20200714085855_b4-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2165\/00003088-199426020-00007","article-title":"Extrahepatic metabolism of drugs in humans","volume":"26","author":"Krishna","year":"1994","journal-title":"Clin Pharmacokinet"},{"key":"key20200714085855_b5-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2165\/00003088-200544040-00002","article-title":"Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: Focus on tamoxifen, paclitaxel and imatinib metabolism","volume":"44","author":"Rochat","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"key20200714085855_b6-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/JCO.2005.02.120","article-title":"Tumoral drug metabolism: Overview and its implications for cancer therapy","volume":"23","author":"Michael","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20200714085855_b7-ol-0-0-10043","first-page":"304","article-title":"P450 enzyme expression patterns in the NCI human tumor cell line panel","volume":"29","author":"Yu","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"key20200714085855_b8-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nm.4038","article-title":"CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma","volume":"22","author":"Noll","year":"2016","journal-title":"Nat Med"},{"key":"key20200714085855_b9-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"key20200714085855_b10-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00384-014-1928-5","article-title":"Advances in the management of colorectal cancer: From biology to treatment","volume":"29","author":"Ahmed","year":"2014","journal-title":"Int J Colorectal Dis"},{"key":"key20200714085855_b11-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1146\/annurev-med-051513-102539","article-title":"Recent therapeutic advances in the treatment of colorectal cancer","volume":"66","author":"Ciombor","year":"2015","journal-title":"Annu Rev Med"},{"key":"key20200714085855_b12-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clcc.2014.11.002","article-title":"A review of the evolution of systemic chemotherapy in the management of colorectal cancer","volume":"14","author":"Gustavsson","year":"2015","journal-title":"Clin Colorectal Cancer"},{"key":"key20200714085855_b13-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2165\/00002018-200528050-00005","article-title":"Benefit-risk assessment of irinotecan in advanced colorectal cancer","volume":"28","author":"Glimelius","year":"2005","journal-title":"Drug Saf"},{"key":"key20200714085855_b14-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1093\/annonc\/mds236","article-title":"ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making","volume":"23","author":"Schmoll","year":"2012","journal-title":"Ann Oncol"},{"key":"key20200714085855_b15-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"153","DOI":"10.14712\/18059694.2015.39","article-title":"Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer","volume":"55","author":"Paulik","year":"2012","journal-title":"Acta Medica (Hradec Kralove)"},{"key":"key20200714085855_b16-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","article-title":"Genetic contribution to variable human CYP3A-mediated metabolism","volume":"54","author":"Lamba","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"key20200714085855_b17-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1172\/JCI119439","article-title":"Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression","volume":"99","author":"Lown","year":"1997","journal-title":"J Clin Invest"},{"key":"key20200714085855_b18-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2210-5-4","article-title":"Distribution of cytochrome P450 2C, 2E1, 3A4, and 3A5 in human colon mucosa","volume":"5","author":"Bergheim","year":"2005","journal-title":"BMC Clin Pharmacol"},{"key":"key20200714085855_b19-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1471-230X-5-34","article-title":"Decreased expression of cytochrome P450 protein in non-malignant colonic tissue of patients with colonic adenoma","volume":"5","author":"Bergheim","year":"2005","journal-title":"BMC Gastroenterol"},{"key":"key20200714085855_b20-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1158\/1078-0432.CCR-04-1848","article-title":"Cytochrome p450 profile of colorectal cancer: Identification of markers of prognosis","volume":"11","author":"Kumarakulasingham","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20200714085855_b21-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"7691","DOI":"10.1007\/s13277-015-3492-1","article-title":"Genetic polymorphisms in cytochrome P450 and clinical outcomes of FOLFIRI chemotherapy in patients with metastatic colorectal cancer","volume":"36","author":"Dong","year":"2015","journal-title":"Tumour Biol"},{"key":"key20200714085855_b22-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.prp.2014.11.002","article-title":"WHO grade related expression of TRAIL-receptors and apoptosis regulators in meningioma","volume":"211","author":"Koschny","year":"2015","journal-title":"Pathol Res Pract"},{"key":"key20200714085855_b23-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20200714085855_b24-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/00008571-199410000-00003","article-title":"CYP3A gene expression in human gut epithelium","volume":"4","author":"Kolars","year":"1994","journal-title":"Pharmacogenetics"},{"key":"key20200714085855_b25-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1165\/ajrcmb.16.3.9070608","article-title":"Expression and localization of CYP3A4 and CYP3A5 in human lung","volume":"16","author":"Anttila","year":"1997","journal-title":"Am J Respir Cell Mol Biol"},{"key":"key20200714085855_b26-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S0940-2993(99)80031-1","article-title":"Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue","volume":"51","author":"Raunio","year":"1999","journal-title":"Exp Toxicol Pathol"},{"key":"key20200714085855_b27-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1365-2125.2005.02389.x","article-title":"Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract","volume":"60","author":"Th\u00f6rn","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"key20200714085855_b28-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1124\/dmd.31.6.755","article-title":"Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism","volume":"31","author":"Westlind-Johnsson","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"key20200714085855_b29-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1124\/dmd.30.10.1108","article-title":"Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA","volume":"30","author":"Koch","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"key20200714085855_b30-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/FPC.0b013e32810f2e58","article-title":"Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues","volume":"17","author":"Bi\u00e8che","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"key20200714085855_b31-ol-0-0-10043","first-page":"52","article-title":"Bimodal distribution of renal cytochrome P450 3A activity in humans","volume":"50","author":"Haehner","year":"1996","journal-title":"Mol Pharmacol"},{"key":"key20200714085855_b32-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1152\/japplphysiol.00322.2003","article-title":"CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults","volume":"95","author":"Givens","year":"2003","journal-title":"J Appl Physiol (1985)"},{"key":"key20200714085855_b33-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1046\/j.1523-1747.2001.01298.x","article-title":"Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes","volume":"116","author":"Baron","year":"2001","journal-title":"J Invest Dermatol"},{"key":"key20200714085855_b34-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/carcin\/20.2.243","article-title":"Characterization of cytochrome P450 expression in human oesophageal mucosa","volume":"20","author":"Lechevrel","year":"1999","journal-title":"Carcinogenesis"},{"key":"key20200714085855_b35-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S1382-6689(96)00075-0","article-title":"CYP3A5 is the major cytochrome P450 3A expressed in human colon and colonic cell lines","volume":"2","author":"Gervot","year":"1996","journal-title":"Environ Toxicol Pharmacol"},{"key":"key20200714085855_b36-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0027-5107(93)90029-F","article-title":"Metabolic differences in colon mucosal cells","volume":"290","author":"McKinnon","year":"1993","journal-title":"Mutat Res"},{"key":"key20200714085855_b37-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0027-5107(97)00038-9","article-title":"The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: Functional and localization studies","volume":"376","author":"Windmill","year":"1997","journal-title":"Mutat Res"},{"key":"key20200714085855_b38-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2174\/1389200003339117","article-title":"Drug-metabolizing enzymes: Mechanisms and functions","volume":"1","author":"Sheweita","year":"2000","journal-title":"Curr Drug Metab"},{"key":"key20200714085855_b39-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1053\/j.gastro.2015.11.046","article-title":"Increased risk of colorectal cancer development among patients with serrated polyps","volume":"150","author":"Erichsen","year":"2016","journal-title":"Gastroenterology"},{"key":"key20200714085855_b40-ol-0-0-10043","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1055\/s-2007-1004268","article-title":"Invasive carcinoma in colorectal adenomas: Multivariate analysis of patient and adenoma characteristics","volume":"29","author":"Nusko","year":"1997","journal-title":"Endoscopy"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T09:48:24Z","timestamp":1594720104000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2019.10043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,14]]},"references-count":40,"URL":"https:\/\/doi.org\/10.3892\/ol.2019.10043","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,14]]}}}